TransCode Therapeutics Surges 58.69% Amid Promising Clinical Advances for TTX-MC138
By ATTN Desk · Editorial oversight: Sean Han
Introduction
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a clinical-stage biotechnology company headquartered in Newton, Massachusetts. Founded in 2016, TransCode focuses on treating metastatic cancer through the design and delivery of RNA therapeutics. Its lead candidate, TTX-MC138, targets microRNA-10b, a biomarker associated with cancer metastasis across multiple tumor types.
Corporate Structure
TransCode operates with a workforce of 11–50 employees, combining expertise in oncology, RNA biology, drug delivery, and clinical development. The company utilizes its proprietary TTX nanoparticle platform to deliver a range of nucleic acid payloads, including antisense oligonucleotides, siRNAs, mRNAs, and genome-editing complexes. In May 2025, Dr. Phillip Zamore, co-founder of Alnylam Pharmaceuticals, joined TransCode’s Science Advisory Board, enhancing the company’s RNA expertise.
RNA therapeutics by Annie Spratt
Recent Developments and News
Since January 2024, TransCode has progressed its platform and pipeline through strategic collaborations, financing, and clinical milestones:
• January 29, 2024 – TransCode announced a co-research agreement with Debiopharm to integrate its TTX delivery platform with Debiopharm’s drug delivery technologies, focusing on nucleic acid therapeutics for cancer.
• March 23, 2025 – The company agreed to sell 10,250,000 shares of common stock and warrants at-the-market under Nasdaq rules for gross proceeds of approximately $10 million. ThinkEquity acted as the sole placement agent.
• March 25, 2025 – TransCode closed the registered direct offering at $0.98 per share (and accompanying warrant), with plans to allocate the net proceeds toward IND-enabling studies, clinical trials of TTX-MC138, and general corporate purposes.
• February 6, 2025 – Pharmacokinetic data from Cohorts 1 and 2 of the TTX-MC138 trial aligned with preclinical and Phase 0 results, indicating no significant safety or dose-limiting toxicities were observed.
• March 13, 2025 – The trial’s Safety Review Committee approved the opening of Cohort 4 based on favorable safety data from Cohort 3.
• March 27, 2025 – The first patient in Cohort 4 was treated with TTX-MC138, bringing the total number of patients treated across dose-escalation cohorts to ten.
• April 16, 2025 – A special meeting of stockholders was scheduled for April 21 to discuss corporate matters.
• May 1, 2025 – Thirteen patients had been treated across four escalating dose levels of TTX-MC138; two patients showed stable disease during treatment.
• May 2, 2025 – TransCode executed a forward stock split to ensure compliance with Nasdaq minimum bid price requirements.
• May 8, 2025 – Fifteen patients had been treated at four dose levels of TTX-MC138, with no dose-limiting toxicities reported and ten patients remaining on study with no evidence of disease progression.
• May 28, 2025 – Dr. Phillip Zamore's appointment to TransCode’s Science Advisory Board was confirmed, adding to the company's RNA therapeutic expertise.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-07-23) | $14.98 |
| Change vs. Previous Close | +58.69% |
| Volume | 504,109 |
| Exchange | NASDAQ (RNAZ) |
Since early 2025, TransCode’s share price has increased, coinciding with clinical progress and corporate developments. The March 25 offering enhanced the company's financial position with approximately $10 million, designated for TTX-MC138 development and wider pipeline advancement. The May 2 stock split was implemented to address compliance thresholds and broaden trading float. The partnership with Debiopharm and the addition of an experienced member to the advisory board aim to support the transition of preclinical findings into later-stage clinical trials.
Market Position and Industry Context
TransCode operates within the RNA oncology sector, where companies focus on nucleic acid modalities targeting cancer. Its emphasis on metastatic disease differentiates it from competitors addressing primary tumors. The proprietary TTX platform enables modular delivery of various therapeutic payloads, supporting early-stage programs such as TTX-siPDL1 (checkpoint modulation), TTX-siLIN28B (inhibition of RNA-binding proteins), TTX-RIGA (activation of innate immunity), TTX-CRISPR, and TTX-mRNA (cancer vaccines). Current industry trends prioritize targeted delivery and precision oncology, and TransCode aims to effectively engage intracellular RNA targets within a competitive landscape.
TL;DR
TransCode’s stock reached $14.98 on July 23, 2025 (+58.69%) following a series of clinical and corporate milestones. In May 2025, the company reported no significant toxicities during dose escalation of TTX-MC138 in 15 patients, executed a compliant stock split, and appointed Dr. Phillip Zamore to its Science Advisory Board. Following a $10 million capital raise in March to fund IND-enabling studies, TransCode is preparing to advance TTX-MC138 into higher-dose cohorts and commence additional clinical trials later in 2025.